Cytokinetics, Incorporated
CYTKHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeCytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating. With a market capitalization of $10.48B, it sits in large-cap territory. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.
Market Cap
$10.48B
Beta
0.36
P/E (TTM)
—
P/E (Fwd)
-16.93
EPS (TTM)
$-7.22
EPS (Fwd)
$-4.45
ROE
—
ROA
-28.1%
Cash
$1.17B
Total Debt
$1.42B
Free CF
-$397.4M
52W Change
39.9%
Annual Financials
Cash vs Debt
Where CYTK stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, CYTK finished 0.45% above its 150-day moving average ($71.61) and 3.20% above its 200-day moving average ($69.70). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CYTK overbought or oversold?
At the September 3, 2026 close, CYTK's RSI(14) was 45.5, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Cytokinetics, Incorporated carries $1.42B in total debt against $1.17B in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. The company is burning cash, with free cash flow at -$397.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Revenue has been relatively flat, moving from $94.6M (2022) to $88.0M (2025).
CYTK's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Cytokinetics, Incorporated's trajectory.